TesoRx Pharma, LLC

TesoRx Pharma, LLC is a privately held pharmaceutical company focused on developing a first-in-class unmodified oral testosterone for androgen deficiency. The company has made significant progress, with phase two clinical study completion and plans to commence phase three dosing by early 2014. The US market for topical, transdermal, and injectable testosterone formulations is currently estimated at $2.1 billion, showing a 90% growth in prescriptions over five years. Analysts project the entire testosterone market to reach $5 billion by 2017. The main unmet need in the market is a safe and effective oral treatment regimen, with studies suggesting that it could potentially cannibalize over 70% of existing treatments once introduced. TesoRx Pharma operates within the biotechnology, health care, and health and wellness industries and is headquartered in the United States. The company's last investment, an angel investment, occurred on 12 November 2014. Although specific details about the investors involved in this round are not provided, TesoRx Pharma's pioneering approach to addressing a significant market need and its progress in clinical studies make it a compelling prospect for potential venture capital investment.